Smart scans may guide breast cancer therapy

NCT ID NCT06245889

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times

Summary

This study tests whether early PET scans can help doctors adjust chemotherapy and immunotherapy for people with stage 2 or 3 triple negative breast cancer. About 30 participants will receive four cycles of chemo plus the drug pembrolizumab. A PET scan after the first cycle will show if the tumor is shrinking. If it is, they go straight to surgery; if not, they get additional chemo before surgery. The goal is to see if early scan results can predict who needs more intensive treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    RECRUITING

    Baltimore, Maryland, 21287, United States

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    RECRUITING

    Baltimore, Maryland, 21287, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.